Thromboprophylaxis in the cancer patient

P. A. Thodiyil, D. C. Walsh, A. K. Kakkar

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations

Abstract

Cancer patients not undergoing treatment and without a history of venous thrombosis do not, as a general rule, require prophylaxis. However, venous thromboembolism is of sufficient magnitude in patients undergoing treatment for cancer for thromboprophylaxis to be routinely employed. The mainstay of primary prevention is low molecular weight heparin, while secondary prevention may require warfarin and in some instances vena cava filters. The duration of prophylaxis should usually last for the period of treatment, except in the case of pelvic or cerebral radiotherapy where it is continued for 4-12 months beyond the treatment period. The principal role for vena cava filters is on occasions where recurrent thrombosis or haemorrhage complicates anticoagulation.

Original languageEnglish
Pages (from-to)73-80
Number of pages8
JournalActa Haematologica
Volume106
Issue number1-2
DOIs
StatePublished - 2001
Externally publishedYes

Keywords

  • Malignant disease
  • Prophylactic therapy
  • Thromboembolism, venous

Fingerprint

Dive into the research topics of 'Thromboprophylaxis in the cancer patient'. Together they form a unique fingerprint.

Cite this